FDA
-
-
-
-
-
-
-
Indivior To Acquire Opiant Pharmaceuticals
-
-
-
-
-
-
-
Indivior Raises FY 2019 Net Revenue and Net Income Guidance; Cash at H1 2019 Expected to be Approximately $985m
-
-
-
-
-
-
-
Indivior Announces Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film Authorized Generic
-
-
-
-
-
-
-
Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters
-
-
-
-
-
-
-
Indivior Applauds Enactment of the SUPPORT for Patients and Communities Act of 2018
-
-
-
-
-
-
-
DURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
-
-
-
-
-
-
-
Indivior Announces Regulatory Submission to Australia's Therapeutic Goods Administration (TGA) for SUBLOCADE™ (Buprenorphine Extended-Release) Injection for the Treatment of Opioid Dependence
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

